Burt D - Search Results

1

Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.

Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L. Langley JM, et al. Among authors: burt d. Vaccine. 2006 Mar 6;24(10):1601-8. doi: 10.1016/j.vaccine.2005.09.056. Epub 2005 Oct 14. Vaccine. 2006. PMID: 16303215 Clinical Trial.

2

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.

Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L. Treanor J, et al. Among authors: burt d. Vaccine. 2006 Jan 16;24(3):254-62. doi: 10.1016/j.vaccine.2005.07.088. Epub 2005 Aug 15. Vaccine. 2006. PMID: 16129526 Clinical Trial.

3

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

Jones T, Allard F, Cyr SL, Tran SP, Plante M, Gauthier J, Bellerose N, Lowell GH, Burt DS. Jones T, et al. Vaccine. 2003 Sep 8;21(25-26):3706-12. doi: 10.1016/s0264-410x(03)00387-6. Vaccine. 2003. PMID: 12922101

4

C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.

Cyr SL, Jones T, Stoica-Popescu I, Burt D, Ward BJ. Cyr SL, et al. Among authors: burt d. Vaccine. 2007 Apr 20;25(16):3228-32. doi: 10.1016/j.vaccine.2007.01.037. Epub 2007 Jan 22. Vaccine. 2007. PMID: 17374422

5

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.

Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ. Cyr SL, et al. Among authors: burt d. Vaccine. 2007 Jul 20;25(29):5378-89. doi: 10.1016/j.vaccine.2007.05.004. Epub 2007 May 24. Vaccine. 2007. PMID: 17561317

6

Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.

Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L. Burt D, et al. Expert Rev Vaccines. 2011 Mar;10(3):365-75. doi: 10.1586/erv.10.172. Expert Rev Vaccines. 2011. PMID: 21434804 Review.

7

Protollin: a novel adjuvant for intranasal vaccines.

Jones T, Cyr S, Allard F, Bellerose N, Lowell GH, Burt DS. Jones T, et al. Vaccine. 2004 Sep 9;22(27-28):3691-7. doi: 10.1016/j.vaccine.2004.03.035. Vaccine. 2004. PMID: 15315848

8

A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice.

Chabot S, Brewer A, Lowell G, Plante M, Cyr S, Burt DS, Ward BJ. Chabot S, et al. Vaccine. 2005 Feb 3;23(11):1374-83. doi: 10.1016/j.vaccine.2004.09.010. Vaccine. 2005. PMID: 15661386

9

Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.

Jones T, Adamovicz JJ, Cyr SL, Bolt CR, Bellerose N, Pitt LM, Lowell GH, Burt DS. Jones T, et al. Vaccine. 2006 Mar 6;24(10):1625-32. doi: 10.1016/j.vaccine.2005.09.052. Epub 2005 Oct 7. Vaccine. 2006. PMID: 16243411

10

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.

Hu MC, Jones T, Kenney RT, Barnard DL, Burt DS, Lowell GH. Hu MC, et al. Vaccine. 2007 Aug 21;25(34):6334-40. doi: 10.1016/j.vaccine.2007.06.017. Epub 2007 Jun 29. Vaccine. 2007. PMID: 17640780 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

615 results

Search Page

Filters